Cochrane Review Group
ENT
76 systematic reviews in ENT ask 806 questions. 36.4% have no studies to answer them, 30.3% rest on very low certainty evidence and 11.5% reach moderate or high certainty.
Reviews
76
Questions
806
current versions
No studies
36.4%
Moderate or high
11.5%
No studies 293 · 36.4%Ungraded 6 · 0.7%Very low 244 · 30.3%Low 170 · 21.1%Moderate 85 · 10.5%High 8 · 1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Thinnest evidence
All no studies and very low questions| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Betahistine vs placebo/no treatment Improvement in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.5 [0.98, 2.29] | 1 study · 70 participants | Very low |
Betahistine vs placebo/no treatment Improvement in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.11 [0.93, 1.32] | 1 study · 62 participants | Very low |
Betahistine vs placebo/no treatment Vertigo global score · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 1 study · 34 participants | Very low |
Betahistine vs placebo/no treatment Change in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 2 studies · 117 participants | Very low |
Betahistine vs placebo/no treatment Change in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 1 study · 214 participants | Very low |
Betahistine vs placebo/no treatment Serious adverse events · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.2 [0.63, 2.29] | 1 study · 220 participants | Very low |
Diuretic vs placebo/no treatment Improvement in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | RR 1.69 [1.13, 2.53] | 1 study · 70 participants | Very low |
Diuretic vs placebo/no treatment Change in vertigo frequency · Ménière’s disease Systemic pharmacological interventions for Ménière’s disease (2023) · Cochrane | no estimate extracted | 1 study · 220 participants | Very low |
Beta‐blockers vs placebo Improvement in vertigo · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | no estimate extracted | NR | No studies |
Beta‐blockers vs placebo Serious adverse events · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | RR 0.63 [0.24, 1.67] | 1 study · 121 participants | Very low |
Calcium channel blockers vs no intervention Improvement in vertigo severity · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | RR 1.45 [1.01, 2.07] | 1 study · 48 participants | Very low |
Calcium channel blockers vs no intervention Improvement in vertigo frequency · people with vestibular migraine Pharmacological interventions for prophylaxis of vestibular migraine (2023) · Cochrane | RR 1.65 [0.8, 3.41] | 1 study · 23 participants | Very low |
Reviews 76
Tranexamic acid for the reduction of bleeding during functional endoscopic sinus surgery
CochraneSoF table
7 questions
Systemic pharmacological interventions for Ménière’s disease
CochraneSoF table
8 questions
Pharmacological interventions for prophylaxis of vestibular migraine
CochraneSoF table
7 questions
Pharmacological interventions for persistent postural‐perceptual dizziness (PPPD)
CochraneSoF table
3 questions
Ventilation tubes (grommets) for otitis media with effusion (OME) in children
CochraneSoF table
16 questions
Lifestyle and dietary interventions for Ménière’s disease
CochraneSoF table
9 questions
Intratympanic corticosteroids for Ménière’s disease
CochraneSoF table
7 questions
Intratympanic gentamicin for Ménière’s disease
CochraneSoF table
6 questions
Positive pressure therapy for Ménière’s disease
CochraneSoF table
4 questions
Surgical interventions for Ménière’s disease
CochraneSoF table
6 questions
Adenoidectomy for otitis media with effusion (OME) in children
CochraneSoF table
16 questions
Autoinflation for otitis media with effusion (OME) in children
CochraneSoF table
4 questions
Antibiotics for otitis media with effusion (OME) in children
CochraneSoF table
8 questions
Topical and oral steroids for otitis media with effusion (OME) in children
CochraneSoF table
16 questions
Non‐pharmacological interventions for prophylaxis of vestibular migraine
CochraneSoF table
10 questions
Pharmacological interventions for acute attacks of vestibular migraine
CochraneSoF table
3 questions
Non‐pharmacological interventions for persistent postural‐perceptual dizziness (PPPD)
CochraneSoF table
11 questions
Intratympanic corticosteroids for sudden sensorineural hearing loss
CochraneSoF table
36 questions
Antihistamines for motion sickness
CochraneSoF table
24 questions
Ginkgo biloba for tinnitus
CochraneSoF table
10 questions
Interventions for the treatment of persistent post‐COVID‐19 olfactory dysfunction
CochraneSoF table
14 questions
Interventions for the prevention of persistent post‐COVID‐19 olfactory dysfunction
CochraneSoF table
17 questions
Topical azole treatments for otomycosis
CochraneSoF table
4 questions
Systemic antibiotics for chronic suppurative otitis media
CochraneSoF table
29 questions
Topical versus systemic antibiotics for chronic suppurative otitis media
CochraneSoF table
21 questions